Off-Label Prescribing in Gynecology: 3 Essentials for Clinicians

When it comes to the consideration of prescription therapies to treat a person with a condition, I always felt the safest when I prescribed a treatment that was covered by the FDA. Somehow, it seemed that I was lowering my medicolegal risk if the patient had an adverse or unintended reaction. Or maybe it seemed more efficient because I could spend less time discussing and charting the best available evidence if the prescription had already been vetted by the FDA.
The problem is that in gynecology, it is nearly unavoidable: the disincentives to formally study drugs in reproductive age and pregnant populations have left many clinical conditions with few or no FDA-approved treatments.
Good examples of off-label treatments used in gynecology include venlafaxine for vasomotor symptoms in menopause, letrozole for PMOS ovulation induction, combined oral contraceptives for the treatment of endometriosis and spironolactone for PMOS hirsutism or acne.

When it comes to the consideration of prescription therapies to treat a person with a condition, I always felt the safest when I prescribed a treatment that was covered by the FDA. Somehow, it seemed that I was lowering my medicolegal risk if the patient had an adverse or unintended reaction. Or maybe it seemed more efficient because I could spend less time discussing and charting the best available evidence if the prescription had already been vetted by the FDA.
The problem is that in gynecology, it is nearly unavoidable: the disincentives to formally study drugs in reproductive age and pregnant populations have left many clinical conditions with few or no FDA-approved treatments.
Good examples of off-label treatments used in gynecology include venlafaxine for vasomotor symptoms in menopause, letrozole for PMOS ovulation induction, combined oral contraceptives for the treatment of endometriosis and spironolactone for PMOS hirsutism or acne.
And, so, the issue is not whether to prescribe off label since I often have no better option. The issue is how, specifically. How do I evaluate the evidence, how do I communicate that evaluation to my patient, and how do I protect myself if things go wrong?
Off-label prescribing is not a grey area or a regulatory workaround. It is legal, common, and frequently the right clinical choice. The result is a field where evidence-based medicine and regulatory approval frequently diverge, and where clinicians carry significant responsibility to bridge that gap for patients.
In a quest to learn more, I have developed three takeaway pearls.

1. Evidence quality matters more than FDA status, so appraise the evidence. Off-label use backed by strong scientific evidence carries the same adverse drug event risk as on-label prescribing (AHR 1.10; 95% CI 0.88–1.38). Without strong evidence, that risk jumps 54% (AHR 1.54; 95% CI 1.37–1.72). Before prescribing off label, locate your evidence tier and appraise available evidence.
   The single most important determinant of safety in off-label prescribing is the quality of evidence supporting the intended use, not FDA status.
   Tier Evidence Source Action
   1 RCTs or meta-analyses Prescribe with confidence — ADE risk equivalent to on-label
   2 Guideline endorsement (ACOG, Menopause Society, ASRM, AUGS) Clinically and legally defensible
   3 Observational studies or case series Use with counseling; document limitations
   4 Expert opinion only Proceed with caution; consider research protocol

2. Your patient is owed an explicit conversation. Off-label prescribing is legal, but informed consent carries a stricter standard than label use. Per ACOG Committee Opinion No. 819, that conversation must cover: (1) the drug is not FDA-approved for this indication, (2) the known and unknown risk-benefit profile, (3) your experience with this use and the state of the evidence, and (4) available alternatives. Courts have held that disclosure extends to what the patient considers important, not just what the clinician deems clinically relevant. Document the components of shared decision making.

3. No evidence + no consent = your highest-risk scenario. Approximately 73% of off-label prescriptions across US practice lack strong scientific support. In that category, adverse event rates are elevated, and medicolegal exposure is real, particularly when informed consent was not documented. Off-label prescribing that is guideline-endorsed and properly disclosed is defensible. Off-label prescribing based on habit, convenience, or anecdote, without a consent conversation, is not.
   References
   Eguale T, Buckeridge DL, Verma A, et al. Association of Off-label Drug Use and Adverse Drug Events in an Adult Population. JAMA Intern Med. 2016;176(1):55–63. doi:10.1001/jamainternmed.2015.6058
   Gazarian M, Horton DB, Carleton B, et al. Optimizing therapeutic decision-making for off-label medicines use: A scoping review and consensus recommendations for improving practice and research. Pharmacoepidemiol Drug Saf. 2023;32(11):1200-1222. doi:10.1002/pds.5640
   Informed Consent and Shared Decision Making in Obstetrics and Gynecology: ACOG Committee Opinion, Number 819. Obstetrics & Gynecology 137(2):p e34-e41, February 2021. | DOI: 10.1097/AOG.0000000000004247
   Shakeel S, Iffat W, Qamar A, Nesar S, Butt F, Siddiqui SN, Rehman H, Rehman AU. Assessment of Knowledge, Attitude, and Practice of Obstetricians and Gynecologists Toward Off-Label Medicine Use in Female Reproductive Health Issues. Front Public Health. 2022 Mar 24;10:829339. doi: 10.3389/fpubh.2022.829339. PMID: 35400076; PMCID: PMC8987152.
   Teede HJ, Tay CT, Laven JJE, Dokras A, Moran LJ, Piltonen TT, Costello MF, Boivin J, Redman LM, Boyle JA, Norman RJ, Mousa A, Joham AE. Recommendations From the 2023 International Evidence-based Guideline for the Assessment and Management of Polycystic Ovary Syndrome. J Clin Endocrinol Metab. 2023 Sep 18;108(10):2447-2469. doi: 10.1210/clinem/dgad463. PMID: 37580314; PMCID: PMC10505534.